作者：李红薇1 ，万正韵1 ，严喜胜2

单位：

1.430065湖北省武汉市，武汉科技大学医学部医学院　2.430060湖北省武汉市第三医院心内科

Units：

1.School of Medicine, Wuhan University of Science and Tecnology, Wuhan 430065, China 2.Department of Cardiology, the Third Hospital of Wuhan, Wuhan 430060, China

关键词：

心力衰竭；肾疾病；钠-葡萄糖共转运蛋白2抑制剂；综述

Keywords：

Heart failure; Kidney diseases; Sodium-glucose cotransporter-2 inhibitors; Review

CLC：

R 541.6 R 692

DOI：

10.12114/j.issn.1008-5971.2024.00.023

Funds：

湖北省科技计划项目（2020CFB660）

摘要：

　随着人口老龄化的日益加重，心力衰竭及慢性肾脏病（CKD）的发病率和病死率逐年攀升。心力衰竭 与CKD常合并存在，全球约50%的心力衰竭患者合并CKD，这类患者的预后更差，且其治疗缺乏具体指导。近年来， 新型口服降糖药钠-葡萄糖协同转运蛋白2抑制剂（SGLT2i）在治疗心力衰竭合并CKD方面受到越来越多的关注，其心 脏及肾脏获益为心力衰竭合并CKD患者的治疗提供了新思路。本文对SGLT2i治疗心力衰竭合并CKD患者的心肾保护机 制、临床证据及SGLT2i的不良反应、安全性做一综述。

Abstract：

With the increasing aging of the population, the incidence rate and mortality of heart failure and chronic kidney disease (CKD) rise year by year. Heart failure and CKD often coexist, and about 50% of heart failure patients worldwide have CKD. The prognosis for these patients is worse and there is a lack of specific guidance for the treatment of these patients. In recent years, the novel oral hypoglycemic agent sodium-glucose cotransporter-2 inhibitors (SGLT2i) has received increasing attention in the treatment of heart failure combined with CKD, and its significant cardiac and renal benefits provide new ideas for the treatment of patients with heart failure combined with CKD. This article provides a review of the cardiorenal protective mechanism, clinical evidence, adverse effects and safety of SGLT2i in the treatment of patients with heart failure combined with CKD.

ReferenceList：